Virtu Financial LLC Acquires New Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Virtu Financial LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 138,105 shares of the company’s stock, valued at approximately $3,339,000. Virtu Financial LLC owned about 0.06% of Hims & Hers Health at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of HIMS. State Street Corp lifted its position in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Hims & Hers Health by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock worth $43,448,000 after acquiring an additional 129,416 shares in the last quarter. Finally, Yong Rong HK Asset Management Ltd purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth $41,104,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In other news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 36,460 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $27.09, for a total value of $987,701.40. Following the transaction, the chief executive officer now directly owns 27,918 shares in the company, valued at $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,015,547 shares of company stock valued at $36,146,450. 17.71% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Truist Financial increased their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC increased their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $37.31.

Hims & Hers Health Stock Up 5.8 %

HIMS opened at $34.77 on Friday. The stock has a market cap of $7.72 billion, a PE ratio of 79.02 and a beta of 1.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The business’s fifty day simple moving average is $39.21 and its 200 day simple moving average is $28.69.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.